Evidence map›Paper›PMID 42789435›Full record

ArticleEmerging microbes & infections2026

IS

Yuxuan Liu, Xinyue Dai, Hanxu Hong, Chuwen Zhao, Yun Cao, Linping Fan, Yang Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuxuan LiuDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.
Xinyue DaiDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.
Hanxu HongDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.
Chuwen ZhaoDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.
Yun CaoDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.
Linping FanDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.
Yang LiuDepartment of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cefiderocol (FDC) is a last-resort antimicrobial for the treatment of carbapenem-resistant

Indexed as

Anti-Bacterial AgentsBacterial ProteinsCarbapenem-Resistant EnterobacteriaceaeCarbapenemsCephalosporinsDNA Transposable ElementsKlebsiella InfectionsKlebsiella pneumoniaeCefiderocolDrug Resistance, BacterialHumansMicrobial Sensitivity TestsPhylogenyAnti-Bacterial AgentsBacterial ProteinsCarbapenemsCefiderocolCephalosporinsDNA Transposable Elementscefiderocol resistancecirAiron-limited adaptationIS903BKlebsiella pneumoniae

Identifiers

PMID42789435
PMCPMC13618097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.